| Document |
Document Title |
|
WO/2021/137714A1 |
The invention relates to the field of composite materials used in medicine, more particularly in ophthalmology, for making optical ophthalmological implants, preferably intraocular lenses, intended for vision correction after cataract su...
|
|
WO/2021/137229A1 |
The present disclosure encompasses pharmaceutical composition, kits and methods for enhancing therapeutic compliance.
|
|
WO/2021/129658A1 |
Provided is an application of a fusion protein in treating age-related macular degeneration. Specifically, provided is an application of a bispecific fusion protein that inhibits activation of a complement pathway and a vascular endothel...
|
|
WO/2021/131872A1 |
[Problem] The purpose of the present invention is to provide a lutein-containing oral composition that has improved lutein stability. [Solution] The lutein stability of a lutein-containing oral composition is improved when the lutein is ...
|
|
WO/2021/132565A1 |
The purpose of the present invention is to provide an aqueous suspension composition that contains poorly soluble sirolimus and that is for use in ophthalmology, especially in topical administration of less-invasive eye drops or the like...
|
|
WO/2021/127769A1 |
The present invention pertains to the pharmaceutical sector, and more specifically proposes a composition for treating conjunctivitis. The compound is made of common ingredients popularly known as healthy ingredients with properties rich...
|
|
WO/2021/129579A1 |
A heme derivative and a preparation method and a use thereof. Specifically, provided are a heme derivative as represented by formula I, or pharmaceutically acceptable salts, enantiomers, diastereoisomers, or raceme thereof. The heme deri...
|
|
WO/2021/128997A1 |
A natural plant eye spray and a preparation method therefor. The eye spray comprises: 50-70 parts of folium artemisiae argyi water, 10-20 parts of green tea leaf water, 10-20 parts of chrysanthemum flower water, 5-10 parts of roselle flo...
|
|
WO/2021/132609A1 |
The present invention pertains to an aqueous composition containing a janus kinase inhibitor and a biguanide-based preservative.
|
|
WO/2021/130022A1 |
The present invention relates to a nanoparticle comprising a nanomaterial and at least a first ligand and a second ligand tethered to the nanoparticle. The present invention further relates to a nanoparticle for use as a medicament or di...
|
|
WO/2021/130653A1 |
The present invention relates to a composition which comprises peptides derived from S-Arrestin (retinal arrestin, S-antigen, S-Ag). The composition or peptides may be useful in the prevention and/or suppression of S-Ag autoimmunity, whi...
|
|
WO/2021/129340A1 |
A tandospirone pharmaceutical composition, a preparation method therefor and a use thereof. The tandospirone pharmaceutical composition comprises a pharmaceutical active ingredient, a skeleton material, a filler, a bleaching aid, a lubri...
|
|
WO/2021/130168A1 |
This invention relates to an ophthalmic formulation comprising lifitegrast, an amino compound, a tonicity-adjusting agent and water, wherein the formulation has an osmolality of 150-330 mOsm/kg. The invention also relates to lifitegrast ...
|
|
WO/2021/132673A1 |
Provided is an agent for preventing or treating acute-phase neuromyelitis optica and pain symptoms of neuromyelitis optica, the agent containing an RGMa-inhibiting substance.
|
|
WO/2021/132598A1 |
The present invention relates to an aqueous composition that includes delgocitinib or a salt thereof, and has a pH of 4.0-6.5.
|
|
WO/2021/133000A1 |
The present invention relates to an anti-inflammatory or antiangiogenic pharmaceutical composition comprising at least one selected from the group consisting of sulfated hyaluronic acid and derivatives and salts thereof, wherein the sulf...
|
|
WO/2021/132950A1 |
The present invention relates to a pharmaceutical composition for preventing or treating macular degeneration, wherein the pharmaceutical composition contains aucubin.
|
|
WO/2021/130313A1 |
The invention relates to RNA editing oligonucleotides (EONs) that can bring about specific editing of a target nucleotide (adenosine) in a target RNA molecule in a eukaryotic cell, wherein said oligonucleotide is for use in the treatment...
|
|
WO/2021/130451A1 |
The invention relates to chemical compounds C that are derivatives of norbixine and have tropism for the eye, and are intended to be used in the treatment of eye diseases in mammals, in particular in the context of altering the retinal p...
|
|
WO/2021/123142A1 |
The present invention relates to compounds for treatment of a disease or disorder associated with excessive vascularisation of the eye, such as for instance corneal neovascularisation, neovascularisation of the iris, neovascularisation o...
|
|
WO/2021/122944A1 |
Compositions and methods useful for altering a P347 mutation in a RHO gene.
|
|
WO/2021/127275A1 |
Disclosed herein are otic formulations and compositions comprising GSK-3 modulators. These otic formulations and compositions allow for the delivery of the GSK-3 modulator to inner ear to: increase SGN density and/or branching; increase ...
|
|
WO/2021/120937A1 |
The present invention provides an application of transthyretin serving as a carrier for a protein and/or polypeptide drug to enter an eye through an eye barrier. The transthyretin is a protein consisting of amino acid as shown in SEQ ID ...
|
|
WO/2021/125800A1 |
The present application relates to a compound for inhibiting an angiogenesis factor, and a use thereof. Furthermore, the present application relates to a method for treating angiogenic diseases by using the compound.
|
|
WO/2021/127301A1 |
4-phenyl-N-(phenyl)thiazol-2-amine and 4-(pyridin-3-yl)-N-( phenyl) thiazol-2-amine derivatives and the corresponding thiadiazole, thiophene, oxazole, oxadiazole, imidazole and triazole derivatives and related compounds as aryl hydrocarb...
|
|
WO/2021/127124A1 |
This disclosure relates to a drug delivery system comprising an intraocular pressure lowering agent, a neurotrophic agent, such as a CNTF compound, a C-type Natriuretic Peptide (CNP) compound, a Tie-2 agonist, a Natriuretic Peptide Recep...
|
|
WO/2021/127480A1 |
In some aspects, the present disclosure provides compounds of the formula: (I) and (II), wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions pro...
|
|
WO/2021/127302A1 |
2-(1H-lndole-3-carbonyl)-thiazole-4-carboxamide derivatives and the corresponding imidazole, oxazole and thiophene derivatives and related compounds as aryl hydrocarbon receptor (AHR) agonists for the treatment of angiogenesis implicated...
|
|
WO/2021/125263A1 |
An objective of the present invention is to provide a novel drug delivery means that targets neovascularization. An objective of the present invention is to provide a novel drug delivery means that targets induced vascular permeability. ...
|
|
WO/2021/125345A1 |
Provided is a vasodilator that can dilate a blood vessel even in an environment where ROS are present. This vasodilator includes the compound represented by formula (1) or a salt thereof. In formula (1), ring A and ring B may be the sa...
|
|
WO/2021/119902A1 |
The present invention provides use of substance A in the preparation of a medicament. The substance A is a naphthylurea compound as shown in formula I, a pharmaceutically acceptable salt thereof, a solvate thereof, a solvate of the pharm...
|
|
WO/2021/125852A1 |
The present invention relates to a novel injectable composition, and provides an injectable composition containing a VEGFR extracellular domain-IgG Fc domain fusion protein, the injectable composition comprising, in an aqueous medium, a ...
|
|
WO/2021/127052A1 |
This disclosure relates to a drug delivery system comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, a tumor necrosis factor-α (TNF-α) or TNF receptor (TNFR) inhibitor, a mi...
|
|
WO/2021/118796A1 |
This invention provides gene expression profiles useful for diagnosing atrial fibrillation in ischemic stroke and for distinguishing atrial fibrillation in ischemic stroke from arterial (large vessel) stroke or embolic stroke of undeterm...
|
|
WO/2021/114662A1 |
Uses of CYP4V2 and RdCVF in preparation of drugs. The drugs are used for treating, relieving and/or preventing diseases or symptoms associated with atrophy of retinal pigment epithelium (RPE). A separated nucleic acid molecule, comprisin...
|
|
WO/2021/115317A1 |
Provided is a recombinant nucleic acid, comprising: a mitochondrial targeting sequence; a mitochondrial protein coding sequence, wherein said mitochondrial protein coding sequence encodes a polypeptide comprising a mitochondrial protein;...
|
|
WO/2021/119353A1 |
Disclosed herein is a medical device for extended release of drugs. The device is a self-retaining implantable drug delivery device embedded with one or more drug depots that release of a therapeutic agent in a controlled manner. Each en...
|
|
WO/2021/115495A1 |
The present invention relates to a sulfur-containing heterocyclic compound, characterized by: a compound represented by the following structural formula (I) or stereoisomer thereof, a geometric isomer, a tautomer, a racemate, a deuterate...
|
|
WO/2021/116257A1 |
The present invention relates to a compounds of general formula (I) inhibiting lysophosphatidic acid receptor 2 (LPA2), particularly the invention relates to compounds that are thienopyrimidine derivatives, methods of preparing such comp...
|
|
WO/2021/119447A1 |
Embodiments of the disclosure encompass methods and compositions for the treatment of medical conditions in which cell regeneration is in need, including neural cells. In specific embodiments, the cell are retinal cells and include Müll...
|
|
WO/2021/116203A1 |
The present invention relates a composition comprising saffron or at least one saffron component, quercetin or a derivative thereof, and/or apigenin or a derivative thereof, for use in the prevention and/or in the treatment of severe all...
|
|
WO/2021/117846A1 |
The purpose of the present invention is to provide a compound having an inhibitory activity against a PDGF receptor kinase. The present invention includes, for example, a compound represented by formula [1] or a pharmaceutically accept...
|
|
WO/2021/116259A1 |
The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 2 (LPA2), particularly the invention relates to compounds that are aromatic amido derivatives, methods of preparing such compound...
|
|
WO/2021/116290A1 |
The present invention concerns an anti-sortilin antibody or an antigen binding fragment thereof, for use in the treatment or prevention of a disease of the eye, in particular diseases or disorders of the retina, the choroid and/or the op...
|
|
WO/2021/116260A1 |
The present invention relates to a compounds of general formula (I) inhibiting lysophosphatidic acid receptor 2 (LPA2), particularly the invention relates to compounds that are quinazoline derivatives, methods of preparing such compounds...
|
|
WO/2021/116679A1 |
The present invention relates to treatments of diabetic macular edema (DME) and impaired visual acuity, comprising intravitreally administering the compound of formula (A) (or a pharmaceutically acceptable salt and/or solvate thereof): F...
|
|
WO/2021/067823A9 |
The invention provides compositions and methods for reducing oxygen concentration in the environment of or promoting the expression or function of at least one hypoxia inducible factor (HIF) in one or more dysfunctional meibomian glands ...
|
|
WO/2021/113506A1 |
Provided are certain ATM kinase inhibitors of Formula (I). Also provided herein are compositions of such compounds, and methods of their use.
|
|
WO/2021/113763A1 |
Provided herein are Class 2 Type V CRISPR:gNA systems comprising Class 2 Type V CRISPR polypeptides (e.g. CasX), guide nucleic acids (gNA), and optionally donor template nucleic acids useful in the modification of a RHO gene. The systems...
|
|
WO/2021/111358A1 |
The present invention relates to budesonide, or a salt thereof, or mixtures thereof for ophthalmic use in a method for the curative treatment of an eye disorder or ailment or disease in a subject in need. Further, the present invention r...
|
